Silk Road Medical (SILK) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

SILK Stock Forecast


Silk Road Medical stock forecast is as follows: an average price target of $30.58 (represents a 11.24% upside from SILK’s last price of $27.49) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

SILK Price Target


The average price target for Silk Road Medical (SILK) is $30.58 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $46.00 to $20.00. This represents a potential 11.24% upside from SILK's last price of $27.49.

SILK Analyst Ratings


Buy

According to 7 Wall Street analysts, Silk Road Medical's rating consensus is 'Buy'. The analyst rating breakdown for SILK stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Silk Road Medical Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 18, 2024Frank TakkinenLake Street$27.50$26.802.59%0.04%
Jun 14, 2024David ToungArgus Research$32.00$21.1951.01%16.41%
May 01, 2024Adam MaederPiper Sandler$20.00$18.269.53%-27.25%
Apr 03, 2024Frank TakkinenLoop Capital Markets$28.00$17.4360.64%1.86%
Mar 07, 2024Steve SilverArgus Research$24.00$15.9850.19%-12.70%
Sep 06, 2023Suraj KaliaOppenheimer$30.00$19.1456.74%9.13%
Jul 18, 2022-Stifel Nicolaus$46.00$39.3616.86%67.33%
Apr 06, 2022Adam MaederPiper Sandler$43.00$42.970.07%56.42%
Row per page
Go to

The latest Silk Road Medical stock forecast, released on Jun 18, 2024 by Frank Takkinen from Lake Street, set a price target of $27.50, which represents a 2.59% increase from the stock price at the time of the forecast ($26.80), and a 0.04% increase from SILK last price ($27.49).

Silk Road Medical Price Target by Period


1M3M12M
# Anlaysts--5
Avg Price Target--$26.30
Last Closing Price$27.49$27.49$27.49
Upside/Downside-100.00%-100.00%-4.33%

In the current month, the average price target of Silk Road Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Silk Road Medical's last price of $27.49. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jun 18, 2024Lake StreetBuyHoldDowngrade
May 01, 2024Piper SandlerNeutralNeutralHold
Apr 29, 2024Lake StreetBuyBuyHold
Apr 03, 2024Lake StreetBuyBuyHold
Jan 19, 2024Raymond James-BuyUpgrade
Sep 06, 2023Oppenheimer-OutperformInitialise
Jul 12, 2023J.P. Morgan-NeutralDowngrade
May 22, 2023Argus ResearchBuyBuyHold
May 15, 2023Wolfe Research-UnderperformDowngrade
Apr 03, 2023CitigroupNeutralBuyUpgrade
Row per page
Go to

Silk Road Medical's last stock rating was published by Lake Street on Jun 18, 2024. The company Downgrade its SILK rating from "Buy" to "Hold".

Silk Road Medical Financial Forecast


Silk Road Medical Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Revenue---------$44.44M$45.30M$40.13M$40.07M$37.37M$33.17M$28.02M$28.27M$24.70M$26.46M$22.05M$21.13M$20.07M$15.09M$18.93M$18.63M$17.03M$14.93M$12.77M
Avg Forecast$58.94M$55.20M$55.16M$52.45M$50.91M$48.75M$49.74M$44.67M$41.93M$44.53M$43.24M$40.69M$37.35M$33.40M$31.04M$27.10M$25.91M$24.32M$25.34M$21.29M$21.35M$19.59M$9.47M$17.33M$17.97M$15.90M$13.64M$12.19M
High Forecast$58.94M$55.20M$55.16M$52.45M$50.91M$49.62M$49.74M$44.67M$42.34M$44.69M$43.24M$40.69M$37.35M$33.40M$31.04M$27.10M$25.91M$24.32M$25.34M$21.29M$21.35M$19.59M$9.47M$17.33M$17.97M$15.90M$13.64M$12.19M
Low Forecast$58.94M$55.20M$55.16M$52.45M$50.91M$47.60M$49.74M$44.67M$41.70M$44.36M$43.24M$40.69M$37.35M$33.40M$31.04M$27.10M$25.91M$24.32M$25.34M$21.29M$21.35M$19.59M$9.47M$17.33M$17.97M$15.90M$13.64M$12.19M
# Analysts1111242475632222345663332234
Surprise %---------1.00%1.05%0.99%1.07%1.12%1.07%1.03%1.09%1.02%1.04%1.04%0.99%1.02%1.59%1.09%1.04%1.07%1.09%1.05%

Silk Road Medical's average Quarter revenue forecast for Dec 23 based on 7 analysts is $41.93M, with a low forecast of $41.70M, and a high forecast of $42.34M. SILK's average Quarter revenue forecast represents a -5.63% decrease compared to the company's last Quarter revenue of $44.44M (Sep 23).

Silk Road Medical EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111242475632222345663332234
EBITDA---------$-13.67M$-11.77M$-13.79M$-10.88M$-8.61M$-14.12M$-16.06M$-13.49M$-12.76M$-9.45M$-9.67M$-15.59M$-8.75M$-8.82M$-8.41M$-6.75M$-6.51M$-10.44M$-22.47M
Avg Forecast$-24.87M$-23.29M$-23.27M$-22.13M$-21.48M$-20.57M$-20.98M$-15.59M$-17.69M$-18.79M$-18.24M$-14.17M$-12.37M$-14.09M$-13.09M$-12.88M$-10.93M$-10.26M$-10.69M$-11.66M$-9.01M$-8.27M$-3.99M$-8.14M$-7.58M$-6.71M$-5.75M$-1.23B
High Forecast$-24.87M$-23.29M$-23.27M$-22.13M$-21.48M$-20.08M$-20.98M$-12.47M$-17.59M$-18.72M$-18.24M$-11.34M$-9.89M$-14.09M$-13.09M$-10.31M$-10.93M$-10.26M$-10.69M$-9.33M$-9.01M$-8.27M$-3.99M$-6.51M$-7.58M$-6.71M$-5.75M$-984.86M
Low Forecast$-24.87M$-23.29M$-23.27M$-22.13M$-21.48M$-20.93M$-20.98M$-18.70M$-17.86M$-18.86M$-18.24M$-17.00M$-14.84M$-14.09M$-13.09M$-15.46M$-10.93M$-10.26M$-10.69M$-13.99M$-9.01M$-8.27M$-3.99M$-9.77M$-7.58M$-6.71M$-5.75M$-1.48B
Surprise %---------0.73%0.65%0.97%0.88%0.61%1.08%1.25%1.23%1.24%0.88%0.83%1.73%1.06%2.21%1.03%0.89%0.97%1.81%0.02%

undefined analysts predict SILK's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Silk Road Medical's previous annual EBITDA (undefined) of $NaN.

Silk Road Medical Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111242475632222345663332234
Net Income---------$-12.79M$-13.48M$-16.01M$-12.60M$-11.41M$-14.64M$-17.40M$-15.33M$-13.88M$-10.54M$-10.69M$-16.76M$-10.31M$-10.35M$-9.94M$-8.29M$-8.01M$-11.96M$-24.16M
Avg Forecast$-11.59M$-12.48M$-12.92M$-15.21M$-13.98M$-15.11M$-14.81M$-16.74M$-16.67M$-13.97M$-15.42M$-15.21M$-13.47M$-17.90M$-17.78M$-13.83M$-14.15M$-12.89M$-14.47M$-12.89M$-11.07M$-11.30M$-14.60M$-9.62M$-10.57M$-10.70M$-10.77M$-1.32B
High Forecast$-11.59M$-12.48M$-12.92M$-15.21M$-13.98M$-13.43M$-14.81M$-13.39M$-12.92M$-13.97M$-15.42M$-12.17M$-10.77M$-17.90M$-17.78M$-11.07M$-14.15M$-12.89M$-14.47M$-10.31M$-11.07M$-11.30M$-14.60M$-7.70M$-10.57M$-10.70M$-10.77M$-1.06B
Low Forecast$-11.59M$-12.48M$-12.92M$-15.21M$-13.98M$-16.79M$-14.81M$-20.08M$-23.33M$-13.97M$-15.42M$-18.26M$-16.16M$-17.90M$-17.78M$-16.60M$-14.15M$-12.89M$-14.47M$-15.47M$-11.07M$-11.30M$-14.60M$-11.54M$-10.57M$-10.70M$-10.77M$-1.59B
Surprise %---------0.92%0.87%1.05%0.94%0.64%0.82%1.26%1.08%1.08%0.73%0.83%1.51%0.91%0.71%1.03%0.78%0.75%1.11%0.02%

Silk Road Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SILK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Silk Road Medical SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111242475632222345663332234
SG&A---------$36.01M$35.83M$34.08M$32.52M$28.82M$27.70M$27.27M$27.59M$25.05M$22.55M$21.19M$20.87M$19.20M$15.76M$19.69M$18.16M$17.06M$14.13M$13.87M
Avg Forecast$54.34M$50.88M$50.85M$48.35M$46.93M$44.94M$45.86M$27.37M$38.66M$41.05M$39.86M$24.88M$25.30M$30.79M$28.61M$22.62M$23.88M$22.42M$23.36M$19.63M$19.68M$18.06M$8.73M$15.97M$16.57M$14.66M$12.57M$11.24M
High Forecast$54.34M$50.88M$50.85M$48.35M$46.93M$45.75M$45.86M$32.84M$39.03M$41.20M$39.86M$29.86M$30.35M$30.79M$28.61M$27.14M$23.88M$22.42M$23.36M$19.63M$19.68M$18.06M$8.73M$15.97M$16.57M$14.66M$12.57M$11.24M
Low Forecast$54.34M$50.88M$50.85M$48.35M$46.93M$43.89M$45.86M$21.89M$38.45M$40.90M$39.86M$19.90M$20.24M$30.79M$28.61M$18.09M$23.88M$22.42M$23.36M$19.63M$19.68M$18.06M$8.73M$15.97M$16.57M$14.66M$12.57M$11.24M
Surprise %---------0.88%0.90%1.37%1.29%0.94%0.97%1.21%1.16%1.12%0.97%1.08%1.06%1.06%1.81%1.23%1.10%1.16%1.12%1.23%

Silk Road Medical's average Quarter SG&A projection for Dec 23 is $38.66M, based on 7 Wall Street analysts, with a range of $38.45M to $39.03M. The forecast indicates a 7.35% rise compared to SILK last annual SG&A of $36.01M (Sep 23).

Silk Road Medical EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
# Analysts1111242475632222345663332234
EPS---------$-0.33$-0.35$-0.42$-0.33$-0.32$-0.42$-0.50$-0.44$-0.40$-0.31$-0.31$-0.49$-0.31$-0.32$-0.32$-0.27$-0.26$-0.42$-0.84
Avg Forecast$-0.29$-0.32$-0.33$-0.38$-0.35$-0.38$-0.37$-0.40$-0.42$-0.35$-0.39$-0.40$-0.38$-0.45$-0.45$-0.37$-0.36$-0.33$-0.37$-0.39$-0.28$-0.29$-0.37$-0.31$-0.27$-0.27$-0.27$-0.32
High Forecast$-0.29$-0.32$-0.33$-0.38$-0.35$-0.34$-0.37$-0.40$-0.33$-0.35$-0.39$-0.40$-0.38$-0.45$-0.45$-0.37$-0.36$-0.33$-0.37$-0.39$-0.28$-0.29$-0.37$-0.31$-0.27$-0.27$-0.27$-0.32
Low Forecast$-0.29$-0.32$-0.33$-0.38$-0.35$-0.42$-0.37$-0.40$-0.59$-0.35$-0.39$-0.40$-0.38$-0.45$-0.45$-0.37$-0.36$-0.33$-0.37$-0.39$-0.28$-0.29$-0.37$-0.31$-0.27$-0.27$-0.27$-0.32
Surprise %---------0.94%0.90%1.05%0.88%0.71%0.94%1.35%1.23%1.23%0.85%0.79%1.75%1.09%0.87%1.04%1.01%0.96%1.54%2.66%

According to undefined Wall Street analysts, Silk Road Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SILK previous annual EPS of $NaN (undefined).

Silk Road Medical Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
SGHTSight Sciences$4.66$10.25119.96%Hold
NPCENeuroPace$6.37$12.88102.20%Buy
FNAParagon 28$6.06$11.5089.77%Buy
OFIXOrthofix Medical$17.33$31.0078.88%-
LUNGPulmonx$7.12$11.9367.56%Buy
TMDXTransMedics Group$84.97$126.7549.17%Buy
SIBNSI-BONE$13.63$20.0046.74%Buy
LIVNLivaNova$49.01$70.5043.85%Buy
KIDSOrthoPediatrics$28.74$39.6037.79%Buy
RXSTRxSight$51.25$70.1136.80%Buy
NARIInari Medical$48.93$66.1135.11%Buy
SILKSilk Road Medical$27.49$30.5811.24%Buy

SILK Forecast FAQ


Yes, according to 7 Wall Street analysts, Silk Road Medical (SILK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of SILK's total ratings.

Silk Road Medical (SILK) average price target is $30.58 with a range of $20 to $46, implying a 11.24% from its last price of $27.49. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for SILK stock, the company can go up by 11.24% (from the last price of $27.49 to the average price target of $30.58), up by 67.33% based on the highest stock price target, and down by -27.25% based on the lowest stock price target.

SILK's highest twelve months analyst stock price target of $46 supports the claim that Silk Road Medical can reach $40 in the near future.

Silk Road Medical's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $194.07M (high $194.95M, low $192.93M), average EBITDA is $-78.616M (high $-75.016M, low $-82.102M), average net income is $-60.637M (high $-55.611M, low $-65.664M), average SG&A $165.1M (high $171.38M, low $158.57M), and average EPS is $-1.511 (high $-1.468, low $-1.553). SILK's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $221.74M (high $221.74M, low $221.74M), average EBITDA is $-93.55M (high $-93.55M, low $-93.55M), average net income is $-52.201M (high $-52.201M, low $-52.201M), average SG&A $204.42M (high $204.42M, low $204.42M), and average EPS is $-1.317 (high $-1.317, low $-1.317).

Based on Silk Road Medical's last annual report (Dec 2022), the company's revenue was $138.64M, beating the average analysts forecast of $128.88M by 7.57%. Apple's EBITDA was $-49.667M, missing the average prediction of $-52.433M by -5.28%. The company's net income was $-58.016M, missing the average estimation of $-62.979M by -7.88%. Apple's SG&A was $116.32M, beating the average forecast of $107.32M by 8.38%. Lastly, the company's EPS was $-1.62, missing the average prediction of $-1.649 by -1.73%. In terms of the last quarterly report (Sep 2023), Silk Road Medical's revenue was $44.44M, missing the average analysts' forecast of $44.53M by -0.21%. The company's EBITDA was $-13.671M, missing the average prediction of $-18.786M by -27.23%. Silk Road Medical's net income was $-12.788M, missing the average estimation of $-13.968M by -8.45%. The company's SG&A was $36.01M, missing the average forecast of $41.05M by -12.28%. Lastly, the company's EPS was $-0.33, missing the average prediction of $-0.353 by -6.39%